Swarajya Logo
  • Morning Brief
  • States
  • Politics
  • Economy
  • Business
  • Culture
  • Infra
  • Defence
  • World
  • Books
  • Ideas
  • Science
  • Technology
  • Heritage
  • Archives
  • Our Views
  • Magazine
  • Headlines
  • Store

Immune Response

First-Ever Chikungunya Vaccine Could Be On The Horizon After Trials Show 99 Per Cent Immune Response

Swarajya News Staff
2y News Brief
image

Gap Between Two Doses Of Sputnik V COVID Vaccine Can Be Extended Up To 180 Days, Says RDIF

Swarajya Staff
3y Insta
image

Bharat Biotech Covaxin Safe, Generates Immune Response Against COVID-19: Study Published In British Medical Journal Lancet

Swarajya Staff
4y Insta
image

Covid-19 Antibodies May Provide Immunity For At Least Five Months, Finds New Study

IANS
4y Insta
image

Safe And Effective Vaccine Against Covid-19 To Be A 'Reality' By Year-End, Says US' Top Infectious Disease Expert

IANS
4y News Brief
image

US FDA Authorises Blood Purification Device To Treat COVID-19 Patients With Serious Conditions

Swarajya Staff
5y Insta
image

Get Swarajya in your inbox.


About Swarajya

Shaping the modern Indian's worldview, speaking on behalf of those invested in the cultural and economic prosperity of India. Published since 1956.


Swarajya is a publication by Kovai Media Private Limited.

editor@swarajyamag.com

Useful Links

  • About Us
  • Subscriptions Support
  • Editorial Philosophy
  • Press Kit
  • Privacy Policy
  • Terms of Use
  • Code of Conduct
  • Plagiarism Policy
  • Refund & Cancellation Policy

Useful Links

  • About Us
  • Subscriptions Support
  • Editorial Philosophy
  • Press Kit
  • Privacy Policy
  • Terms of Use
  • Code of Conduct
  • Plagiarism Policy
  • Refund & Cancellation Policy

Participate

  • Contact Us
  • Write for us
  • Style Guide
  • Jobs

Stay Connected

  • Artboard 2 Copy 6Created with Sketch.
    Artboard 2 Copy 10Created with Sketch.
    Artboard 2 Copy 7Created with Sketch.
    Artboard 2 Copy 9Created with Sketch.
  • Andriod Logo
  • IOS Logo